



HEALTHCARE PROVIDERS REMINDER CARD

Erivedge® Reminder for Healthcare Providers.

Female patients of childbearing potential must:

- Take monthly pregnancy test even if patient becomes amenorrhoeic.
- Always use recommended contraception while taking Erivedge® and for 24 months after their final dose.
- Not breast-feed during treatment and for 24 months after their final dose.

Male patients must:

- Use condoms (with spermicide if available) when having sex with a female partner while taking Erivedge® and for 2 months after their final dose.
- Not donate semen during treatment and for 2 months after the final dose of this medicine.

The patient must contact you urgently if a pregnancy is suspected in a female patient or in a female partner of a male patient.

You must:

- Assess pregnancy status, counsel the patient for teratogenicity risk, and refer the patient and female partner to a specialist.
- Report all confirmed pregnancies to Roche.

All patients must:

- Never give this medicine to another person.
- Return the unused capsules at the end of the treatment (disposal will depend on local requirements).
- Not donate blood during treatment and for 24 months after their final dose.

Further information on Erivedge® side effects and pregnancy prevention can be found in the Erivedge® PI and Patient Leaflet.

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form:

<http://forms.gov.il/globaldata/getsequence/getsequence.aspx?formType=AdversEffectMedic@moh.health.gov.il> or by email adr@moh.health.gov.il

Or to Roche Affiliate Safety Reporting contact information:

Israel.DrugSafety@roche.com, Phone: 09-9737722 Fax: 09-9737736

